Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces the initiation of a Phase III clini...
Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade gl...
U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for trenibotulinumtoxinE (TrenibotE) related to manufacturing processes; ...
OrganaBio, LLC ("OrganaBio"), a vertically integrated blood and cell products and services company delivering end-to-end solutions for cell and gene ther...
Marks AbbVie's largest-ever capital investment in a single campus since its inception Investment demonstrates continued progress a...
10x Science, which builds frontier AI for molecular-level protein characterization across the life sciences, today announced the closing of its $4.8M seed ...
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, announced a strategic partnership with Turbine, a ...
Kelonia's lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory mul...
This marks the third milestone achieved under the collaboration and reflects the steady progress of the pipeline Under the terms of the agreement, Nxe...
The demand for nucleic acid therapeutics (NATs) is rapidly altering the therapeutic landscape across a wide range of diseases. Recent industry data highlig...
BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pne...
Phase two collaboration aims to expand access to streamlined genomic workflows for infectious disease research Cepheid, a Danaher company and a leader i...
Strategic partnership enables upskilling of Novo Nordisk’s workforce and places the company at the forefront of AI transformation in healthcare ...
In this exclusive BioPharma Boardroom interaction, Thierry Van Nieuwenhove, CEO of Quotient Sciences, explores why nearly 90% of drug candidates fail and w...
© 2026 Biopharma Boardroom. All Rights Reserved.
